Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Warfarin Dosing Clear all

Conditions: Blood Clotting
Interventions: warfarin pharmacogenetic dosing, Warfarin; Genetic · Drug
Lead sponsor: Robert Pendleton; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Warfarin, Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Thromboembolism, Blood Coagulation Disorders, Cardiovascular Disease, Vascular Disease
Interventions: Patient Self-Monitoring vs Anticoagulation Clinic; Other
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 21 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Blood Coagulation Disorders
Interventions: Warfarin Dosing; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Thromboembolism
Interventions: IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment; Genetic · Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 2,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions: Apixaban, Warfarin; Drug
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk
Interventions: Balfaxar, Kcentra; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 3,574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Left Ventricular Thrombus
Interventions: Apixaban, Warfarin; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Information Seeking Behavior
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Venous Thromboembolism, Bleeding
Interventions: Pharmacogenetic-based warfarin dosing, Usual care warfarin dosing; Genetic · Other
Lead sponsor: Gwen McMillin; Other
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Standard of care or genotyping dosing of warfarin dosing; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atrial Fibrillation (AF)
Interventions: discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation; Behavioral · Drug · Procedure
Lead sponsor: China National Center for Cardiovascular Diseases; Government
Eligibility: 18 Years and older
Enrollment: 3,160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthroplasty, Replacement, Knee
Interventions: YM150, Warfarin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 44
States / cities: Mobile, Alabama • Phoenix, Arizona • Tuscon, Arizona + 35 more

Conditions: Blood Coagulation Disorders
Interventions: Warfarin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
Interventions: Genotype-guided dose determination, Non-genotype guided warfarin dosing; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions: Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma; Drug · Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Patient-Centered Anticoagulation Self-Monitoring in Minority Patients

PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Apixaban Versus Warfarin for Left Ventricular Thrombus

Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities

Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery

Clinical and Economic Implications of Genetic Testing for Warfarin Management

Genotype-Guided Warfarin Therapy Trial

FFP Versus PCC in Intracranial Hemorrhage